N
Nicola Boffini
Researcher at Vita-Salute San Raffaele University
Publications - 12
Citations - 1733
Nicola Boffini is an academic researcher from Vita-Salute San Raffaele University. The author has contributed to research in topics: Retrospective cohort study & Tocilizumab. The author has an hindex of 7, co-authored 11 publications receiving 1238 citations.
Papers
More filters
Journal ArticleDOI
Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study.
Giulio Cavalli,Giacomo De Luca,Corrado Campochiaro,Emanuel Della-Torre,Marco Ripa,Diana Canetti,Chiara Oltolini,Barbara Castiglioni,Chiara Tassan Din,Nicola Boffini,Alessandro Tomelleri,Nicola Farina,Annalisa Ruggeri,Patrizia Rovere-Querini,Giuseppe Di Lucca,S. Martinenghi,Raffaella Scotti,Moreno Tresoldi,Fabio Ciceri,Giovanni Landoni,Alberto Zangrillo,Paolo Scarpellini,Lorenzo Dagna +22 more
TL;DR: In this retrospective cohort study of patients with COVID-19 and ARDS managed with non-invasive ventilation outside of the ICU, treatment with high-dose anakinra was safe and associated with clinical improvement in 72% of patients.
Journal ArticleDOI
Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study.
Corrado Campochiaro,Emanuel Della-Torre,Giulio Cavalli,Giacomo De Luca,Marco Ripa,Nicola Boffini,Alessandro Tomelleri,Elena Baldissera,Patrizia Rovere-Querini,Annalisa Ruggeri,Giacomo Monti,Francesco De Cobelli,Alberto Zangrillo,Moreno Tresoldi,Antonella Castagna,Lorenzo Dagna +15 more
TL;DR: Clinical improvement and mortality were not statistically significant different between tocilizumab and standard treatment patients in this retrospective study on severe COVID-19 patients with hyper-inflammatory features.
Journal ArticleDOI
Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study.
Emanuel Della-Torre,Corrado Campochiaro,Giulio Cavalli,Giacomo De Luca,Angela Napolitano,Salvatore La Marca,Nicola Boffini,Valentina Da Prat,Gaetano Di Terlizzi,Marco Lanzillotta,Patrizia Rovere Querini,Annalisa Ruggeri,Giovanni Landoni,Moreno Tresoldi,Fabio Ciceri,Alberto Zangrillo,Francesco De Cobelli,Lorenzo Dagna +17 more
TL;DR: Overall clinical improvement and mortality in patients with severe COVID-19 pneumonia were not significantly different between sarilumab and standard of care and Sariluab was associated with faster recovery in a subset of patients showing minor lung consolidation at baseline.
Journal ArticleDOI
GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study
Giacomo De Luca,Giulio Cavalli,Corrado Campochiaro,Emanuel Della-Torre,Piera Angelillo,Alessandro Tomelleri,Nicola Boffini,Stefano Tentori,Francesca Mette,Nicola Farina,Patrizia Rovere-Querini,Annalisa Ruggeri,Teresa D'Aliberti,Paolo Scarpellini,Giovanni Landoni,Francesco De Cobelli,John F Paolini,Alberto Zangrillo,Moreno Tresoldi,Bruce C. Trapnell,Fabio Ciceri,Lorenzo Dagna +21 more
TL;DR: This single-centre prospective cohort study examined whether mavrilimumab, an anti-granulocyte–macrophage colony-stimulating factor receptor-α monoclonal antibody, added to standard management, improves clinical outcomes in patients with COVID-19 pneumonia and systemic hyperinflammation.
Journal ArticleDOI
Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study.
Giulio Cavalli,Alessandro Larcher,Alessandro Tomelleri,Corrado Campochiaro,Emanuel Della-Torre,Giacomo De Luca,Nicola Farina,Nicola Boffini,Annalisa Ruggeri,Andrea Poli,Paolo Scarpellini,Patrizia Rovere-Querini,Moreno Tresoldi,Andrea Salonia,Francesco Montorsi,Giovanni Landoni,Antonella Castagna,Fabio Ciceri,Alberto Zangrillo,Lorenzo Dagna +19 more
TL;DR: In this article, the authors compared IL-1 and IL-6 inhibition in patients admitted to hospital with COVID-19, respiratory insufficiency, respiratory infection, and hyperinflammation.